Literatur zu Anakinra (Kineret)

Anakinra bei der rheumatoiden Arthritis

  1. Arend WP, van den Berg WB, Bresnihan B, Watt I, Genant HK. Can novel therapies preserve greater function with rheumatoid arthritis? Targeted IL-1 inhibition. Semin Arthritis Rheum. 2001;30(suppl 2).
  2. Arend WP. Cytokine imbalance pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum. 2001;30:1-6.
  3. van den Berg WB. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum. 2001;30:7-16. 
  4. Bresnihan B, Alvaro-Garcia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-2204.
  5. Bresnihan B. Treatment of rheumatoid arthritis with interleukin-1 receptor antagonist. Ann Rheum Dis. 1999;58(suppl):196-198.
  6. Bresnihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2001;30:17-20.
  7. Bresnihan B, Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford). 2003 May;42 Suppl 2:ii22-8.
  8. den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van den Hoogen FH. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis. 2006 Jun;65(6):760-2 Link
  9. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-24 Link
  10. Cohen SB. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 2004 May;30(2):365-80.
  11. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, Group I. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis.  Arthritis Rheum. 1996;39:1092-1101.
  12. Cunnane G, Cassidy N, Madigan A, Murphy E, Fitzgerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist (IL-1Ra) on the synovial membrane and joints of patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:S138.
  13. Dayer JM et al. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opinion Rheum. 2001;13:170-176.
  14. Gabay C, Arend WP. Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin Immunopathol. 1998;20:229-246.
  15. Fleishmann RM. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents. Clin Exp Rheumatol. 2002 Sep-Oct;20(5 Suppl 27):S35-41. Link
  16. Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003; 48, 927–94 Link
  17. Fleischmann RM. Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford). 2003 May;42 Suppl 2:ii29-35. Link 
  18. Fleischmann R Anakinra in the treatment of rheumatic disease. Expert Rev Clin Immunol. 2006 May;2(3):331-40.
  19. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis. 2006 Aug;65(8):1006-12 Link
  20. Genovese M C, Cohen S B, Moreland L, Lium D, Robbins S, Newmark R. et al Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004 May;50(5):1412-9 Link
  21. Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.  Arthritis Rheum 2000; 41: 2196-204 Link
  22. Jouvenne P, Vannier E, Dinarello CA, Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum. 1998;41:1083-1089.
  23. Karanikolas G, et al. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.  Rheumatology. 2008 Sep;47(9):1384-1388
  24. Langer HE, Missler-Karger B. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol. Int J Clin Pharmacol Res. 2003;23(4):119-28. Link
  25. Lebsack ME, Bloedow DC, Paul CC. Plasma levels of interleukin-1 receptor antagonist following subcutaneous infection in patients with rheumatoid arthritis.  Clin Pharmacol Ther. 1992;51:192.
  26. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD005121. Link
  27. Schiff MH, DiVittorio G, Tesser J, et al. The safety of anakinra n high-risk patients with active rheumatoid arthritis. six-month observations of patients with comorbid conditions. Arthritis Rheum 2004; 50: 1752-60 Link
  28. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MPT, Tugwell P, Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review) Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794 Link
  29. Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, Modafferi D, Schechtman J; 990757 Study Group. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. J Rheumatol. 2004 Apr;31(4):649-54. Link
  30. Thaler K, Chandiramani DV, Hansen RA, Gartlehner G. Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics. 2009;3:485-98. Epub 2009 Dec 29. Link

Anakinra bei CAPS

  1. Alexander T, Klotz O, Feist E, Ruther K, Burmester GR, Pleyer U. Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1 receptor antagonist. Ann Rheum Dis 2005;64:1245–6. Link
  2. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaham B, Jarvis JN, O'Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP, Warren RW, Horn W, Cole JL, Paul SM, Hawkins PN, Pham TH, Snyder C, Wesley RA, Hoffmann SC, Holland SM, Butman JA, Kastner DL. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006; 355: 581–92. Link
  3. Granel B, Serratrice J, Disdier P, Weiller PJ. Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology (Oxford) 2005;44:689-90. Link
  4. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348:2583–4. Link
  5. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 2004 Feb;50(2):607-12. Link
  6. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, Anderson JP, Wanderer AA, Firestein GS. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779–85. Link
  7. Klein AK, Horneff G. Improvement of sensoneurinal hearing loss in a patient with Muckle–Wells syndrome treated with anakinra. Klin Padiatr. 2011;222:266–268 Link
  8. Lepore L, Paloni G, Caorsi R, Alessio M, Rigante D, Ruperto N, Cattalini M, Tommasini A, Zulian F, Ventura A, Martini A, Gattorno M. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr. 2010 Aug;157(2):310-315. Link
  9. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal onset multisystem inflammatory disease. Arthritis Rheum 2005;52: 1283–6. Link 
  10. Miyamae T, Inaba Y, Nishimura G, Kikuchi M, Kishi T, Hara R, Kaneko U, Shinoki T, Imagawa T, Yokokta S. Effect of anakinra on arthropathy in CINCA/NOMID syndrome. Pediatr Rheumatol Online J. 2010 Mar 16;8:9. Link
  11. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, Quartier P. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/ chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2011;62:258–267. Link
  12. E. Ramos, J. I. Aróstegui, S. Campuzano, J. Rius, C. Bousoño, J. Yagüe. Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS) Rheumatology (August 2005) 44 (8): 1072-1073. Link
  13. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaham B, Jarvis JN, O'Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP, Warren RW, Horn W, Cole JL, Paul SM, Hawkins PN, Pham TH, Snyder C, Wesley RA, Hoffmann SC, Holland SM, Butman JA, Kastner DL. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355:581–592. Link
  14. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50: 607–12. Link
  15. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, Anderson JP, Wanderer AA, Firestein GS. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779–85. Link
  16. European Medicines Agency (EMA): Assessment report Anakinra. Link

Anakinra bei Interleukin-1-abhängigen Krankheitsbildern

  1. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012 Aug;11(8):633-52. doi: 10.1038/nrd3800. Link 

Anakinra bei M. Still

  1. Aarntzen EH, van Riel PL, Barrera P: Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution? Ann Rheum Dis 2005, 64:1523-1524. Link
  2. Al-Homood IA: Biologic treatments for adult-onset Still´s disease. Rheumatology (2013), First published online: July 17, 2013. Link
  3. Fautrel B, Borget C, Rozenberg S, Meyer O, Le Loët X, Masson C, Koeger AC, Kahn MF, Bourgeois P: Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 1999, 26:373-378 Link
  4. Fautrel B, Sibilia J, Mariette X, Combe B, Club Rhumatismes et Inflammation: Tumour necrosis factor a blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005, 64:262-266 Link
  5. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005 Jun;52(6):1794-803. Link
  6. Fujii T, Akizuki M, Kameda H, Matsumura M, Hirakata M, Yoshida T, Shinozawa T, Mimori T: Methotrexate treatment in patients with adult onset Still's disease-retrospective study of 13 Japanese cases. Ann Rheum Dis 1997, 56:144-148 Link
  7. Guignard S, Dien G, Dougados M: Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug Anakinra: a case report. Clin Exp Rheumatol. 2007 Sep-Oct;25(5):758-9. Link
  8. Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, Weinblatt ME: Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002, 46:1171-1176 Link
  9. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN: Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 2007, 66:842-843 Link
  10. Kötter I, Wacker A, Koch S, Henes J, Richter C, Engel A, Günaydin I, Kanz L. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007 Dec;37(3):189-97. Epub 2007 Jun 20. Link
  11. Laskari K, Tzioufas AG, and Moutsopoulos HM: Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study, Arthritis Research and Therapy, vol. 13, no. 3, article R91, 2011 Link
  12. Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J, Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP), Club Rhumatismes et Inflammation (CRI): Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008, 67:302-308. Link
  13. Maier J, Birkenfeld G, Pfirstinger J, Schölmerich J, Fleck M, Brühl H: Effective treatment of steroid refractory adult-onset Still's disease with anakinra. J Rheumatol 2008, 35:939-941. Link
  14. Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, Burmester GR: IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis 2010, 69:466-467
  15. Dan Nordström, Ann Knight, Reijo Luukkainen, Ronald van Vollenhoven, Vappu Rantalaiho, Anna Kajalainen, Johan G. Brun, Anne Proven, Lotta Ljung, Hannu Kautiainen and Tom Pettersson: Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study J Rheumatol. 2012, Published online before print August 1, 2012, doi: 10.3899/jrheum.111549 Link
  16. R. Priori, F. Ceccarelli, F. Barone, A. Iagnocco, G. Valesini: Clinical, biological and sonographic response to IL-1 blockade in adult-onset Still’s disease Clinical and Experimental Rheumatology 2008; 26: 933-937 Link
  17. Rudinskaya A, Trock DH: Successful Treatment of a patient with refractory adult onset Still disease with anakinra. J Clin Rheumatol 2003; 9: 330-2.
  18. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still’s disease successfully treated with anakinra. Ann Rheum Dis 2005;64:647–8.
  19. Lahiri, M. & Teng, G.G. A case of refractory adult-onset Still's disease treated with anakinra. Int J Rheum Dis 13, e36-41 (2010).
  20. Moulis, G., Sailler, L., Astudillo, L., Pugnet, G. & Arlet, P. May anakinra be used earlier in adult onset Still disease? Clin Rheumatol 29, 1199-200 (2010).
  21. Mylona, E. et al. Acute hepatitis in adult Still's disease during corticosteroid treatment successfully treated with anakinra. Clin Rheumatol 27, 659-61 (2008).
  22. Raffeiner, B. et al. Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine 78, 100-1 (2011).
  23. Tamaki, H. et al. Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still's disease. Mod Rheumatol 20, 200-4 (2010).
  24. Vordenbaumen, S., Ostendorf, B., Sander, O., Richter, J. & Schneider, M. Continuation of anakinra despite the development of a pruritic rash in an otherwise refractory case of adult-onset Still's disease. Ann Rheum Dis 68, 450-1 (2009).
  25. Woo, P. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease. Ann Rheum Dis 67, 281-2 (2008). 

Anakinra (Kineret) bei systemischer juveniler Arthritis (Still-Syndrom)

  1. Pascual, V., Allantaz, F., Arce, E., Punaro, M. & Banchereau, J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201, 1479-86 (2005).
  2. Quartier, P. et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis (2011).
  3. Gattorno, M. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58, 1505-15 (2008).
  4. Nigrovic, P.A. et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63, 545-55 (2011).
  5. Dewitt, E.M. et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (2012).
  6. Belot, A. et al. ANCA-associated glomerulonephritis in systemic-onset juvenile idiopathic arthritis. Am J Kidney Dis 59, 439-43 (2012).

Anakinra (Kineret) bei familiärem Mittelmeerfieber

  1. Calligaris, L., Marchetti, F., Tommasini, A. & Ventura, A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 167, 695-6 (2008).
  2. Chae, J.J. et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 103, 9982-7 (2006).
  3. Meinzer, U. et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 41, 265-71 (2011).
  4. Mitroulis, I., Papadopoulos, V.P., Konstantinidis, T. & Ritis, K. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med 66, 489-91 (2008).
  5. Moser, C. et al. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transplant 24,676-8 (2009).
  6. Ozen, S., Bilginer, Y., Ayaz, N.A. & Calguneri, M.  Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol (2011)
  7. Petropoulou, A.D., Robin, M., Socie, G. & Galicier, L. Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra. Transplantation 90, 102-3 (2011)
  8. Stankovic Stojanovic, K. et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant (2011)
  9. Bilginer, Y., Ayaz, N.A. & Ozen, S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease. Clin Rheumatol 29, 209-10 (2010).

Anakinra (Kineret) bei Psoriasis-Arthritis

  1. Pontifex, E.K. et al. Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study. Arthritis Res Ther 13, R7 (2011)
  2. Jung, N. et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 29, 1169-73 (2011)

Anakinra (Kineret) bei Spondyloarthritiden

  1. Haibel, H., Rudwaleit, M., Listing, J. & Sieper, J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks.   Ann Rheum Dis. 2005 February; 64(2): 296–298. Link
  2. Bennett, A.N. et al. Sustained response to anakinra in ankylosing spondylitis. Rheumatology (Oxford) 47, 223-4 (2008).
  3. Tan, A.L. et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63, 1041-5 (2004).

Anakinra (Kineret) bei Gicht und anderen Kristallarthropathien

  1. Funck-Brentano, T. et al. First observation of the efficacy of IL-1ra to treat tophaceous gout of the lumbar spine. Rheumatology (Oxford) 50, 622-4 (2011).
  2. Couderc, M., Mathieu, S., Glace, B. & Soubrier, M. Efficacy of anakinra in articular chondrocalcinosis: report of three cases. Joint Bone Spine 79, 330-1 (2012).
  3. McGonagle, D., Tan, A.L., Madden, J., Emery, P. & McDermott, M.F. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 58, 631-3 (2008).
  4. McGonagle, D. et al. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 66, 1683-4 (2007).
  5. So, A., De Smedt, T., Revaz, S. & Tschopp, J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9, R28 (2007).
  6. So, A. Epidemiology: Gout--bad for the heart as well as the joint. Nat Rev Rheumatol 6, 386-7 (2010).
  7. Singh, D. & Huston, K.K. IL-1 inhibition with anakinra in a patient with refractory gout. J Clin Rheumatol 15, 366 (2009).
  8. Gratton, S.B., Scalapino, K.J. & Fye, K.H. Case of anakinra as a steroidsparing agent for gout inflammation. Arthritis Rheum 61, 1268-70 (2009).
  9. Announ, N., Palmer, G., Guerne, P.A. & Gabay, C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 76, 424-6 (2009).
  10. Molto, A., Ea, H.K., Richette, P., Bardin, T. & Liote, F. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine (2012).

Anakinra (Kineret) bei Typ-2-Diabetes

  1. Larsen, C.M. et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32, 1663-8 (2009).
  2. Larsen CM, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517–1526. Link

Anakinra (Kineret) bei der Arthrose

  1. Chevalier, X. et al. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicentre study. J Rheumatol 32, 1317-23 (2005).
  2. Chevalier, X. et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 61, 344-52 (2009).
  3. Bacconnier, L., Jorgensen, C. & Fabre, S. Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann Rheum Dis 68, 1078-9 (2009).
  4. Brown, C., Toth, A. & Magnussen, R. Clinical benefits of intra-articular anakinra for persistent knee effusion.  J Knee Surg 24, 61-5 (2011).

Arbeiten zur Grundlagenforschung

  • Chomarat P, Vannier E, Dechanet J, et al. Balance of IL-1 receptor antagonist/IL-1B in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol. 1995; 1432-1439.
  • Deleuran BW, Shu CQ, Field M, et al. Localization of Interleukin-1 alpha, type 1 Interleukin-1 receptor and Interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol. 1992; 31:801-809.
  • Firestein GS, Boyle DL, Yu C, et al. Synovial Interleukin-1 receptor antagonist and Interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. 1994; 37:644-652.
  • Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human Interleukin-1 inhibitor. Nature. 1990; 343:336-40.
  • Van Lent, PLEM, Fons, AJ, Van De Loo, AEM et al, Major role for Interleukin-1 but not for tumor necrosis factor in early cartilage damage in immune complex in mice. J Rheumatol. 1995; 22:2250-2258 

Sonstige Arbeiten

  1. Arend WP. Cytokines and cellular interactions in inflammatory synovitis (commentary). J Clin Invest. 2001;107:1081-1082.
  2. Bresnihan B, Cunnane G. Interleukin-1 receptor antagonist.  Rheum Dis Clin North Am. 1998;24:615-628.
  3. Granowitz EV, Porat R, Mier JW, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 1992;4:353-360.
  4. Kaiser C, Knight A, Nordström D, Pettersson T, Fransson J, Florin-Robertsson E, Pilström B Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int. 2012 Feb;32(2):295-9. doi: 10.1007/s00296-011-2096-3. Link
Copyright © 1997-2020 rheuma-online
rheuma-online Österreich
 
Alle Texte und Beiträge in rheuma-online wurden nach bestem Wissen und Gewissen erstellt. Irrtümer sind jedoch vorbehalten. Alle Angaben sind ohne Gewähr. Jegliche Haftungsansprüche, insbesondere auch solche, die sich aus den Angaben zu Krankheitsbildern, Diagnosen und Therapien ergeben könnten, sind ausgeschlossen.